Time to Revisit Endpoint Selection in Clinical Trials |Biomedgrid
Journal: American Journal of Biomedical Science & Research (Vol.9, No. 3)Publication Date: 2020-06-23
Authors : Shein-Chung Chow; Patty J Lee;
Page : 247-250
Keywords : Primary Endpoint; Co-primary Endpoint; Utility Function; Therapeutic Index; Treatment;
Abstract
In clinical trials, power calculation is often performed based on a single primary endpoint to determine sample size required for achieving study objective with a desired power at a pre-specified level of significance. In practice, power calculation based on a single primary endpoint has been criticized. First, how to select the single primary endpoint among a group of primary endpoints? Second, a single primary endpoint may not be sufficient to adequately inform complex cohorts, the disease status and/or treatment effect of the test treatment under investigation. Third, different study endpoints with different data types (e.g., continuous versus binary response) may result in different sample sizes. In addition, with a given sample size, some (single) endpoints may achieve the study objective while others fail to do so. In this opinion article, a conceptual innovation is the development of a therapeutic index that fully utilizes information from all relevant study endpoints proposed.
Other Latest Articles
- Peritoneal Dialysis in the Elderly: Modality of Choice During COVID-19 Pandemic |Biomedgrid
- Profile of Some Trace Elements in Selected Traditional Medicines used for Various Aliments in Ebonyi State, Nigeria |Biomedgrid
- INVESTIGATION OF OPTIMIZATION TECHNIQUES FOR NONLINEAR PROGRAMMING PROBLEMS
- USING IMAGE PROCESSING AND MACHINE LEARNING FOR LUNG CANCER DETECTION
- IMPLEMENTATION OF IOT FOR AIR POLLUTION MONITORING
Last modified: 2023-06-16 21:07:48